Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab and mDCF Followed by Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
NCT04719988Phase 2Active, not recruiting
- Sponsor
- CHU de Besançon
- Start
- Jan 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ezabenlimab in anal squamous cell carcinoma (SCCA), sponsored by CHU de Besançon. Started Jan 2022; status: active, not recruiting.
02
Drugs
ezabenlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT04719988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04719988.